Litigation Details for Allergan USA, Inc. v. MSN Laboratories Private Limited (D. Del. 2022)

Allergan USA, Inc. v. MSN Laboratories Private Limited (D. Del. 2022)

Docket		Date Filed	2022-02-09
Court	District Court, D. Delaware	Date Terminated	2023-10-12
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	11,229,627
Link to Docket	External link to docket

Details for Allergan USA, Inc. v. MSN Laboratories Private Limited (D. Del. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-02-09				External link to document

Litigation summary and analysis for: Allergan USA, Inc. v. MSN Laboratories Private Limited (D. Del. 2022)

Last updated: July 5, 2026

Executive summary

Allergan USA, Inc. v. MSN Laboratories Private Limited (1:22-cv-00181) is a Hatch-Waxman patent infringement dispute tied to Allergan’s branded drug and MSN’s proposed generic. The case is filed in the U.S. District Court for the Eastern District of Texas and seeks relief for infringement of Orange Book-listed patents covering the brand’s active ingredient and/or associated formulation and use. The docket posture, asserted patent list, claim construction status, and any settlement or final judgment are not provided in the input, so no complete, decision-grade litigation summary can be produced from the available facts.

Litigation overview: What is Allergan USA v. MSN Laboratories Private Limited (1:22-cv-00181) about?

The case caption indicates a standard Hatch-Waxman framework: a brand sponsor sues a generic applicant for infringement of listed patents after the generic’s Abbreviated New Drug Application (ANDA) filing.

What typically drives this type of case

• Asserted U.S. patents listed in the Orange Book for the brand drug.
• Alleged infringement by the generic’s proposed manufacture, use, sale, and/or offer for sale.
• Legal hooks commonly include 35 U.S.C. §§ 271(e)(2) and related remedies.

What is needed to produce a litigation summary that is accurate

A complete litigation summary must include, at minimum, the asserted patent numbers (and which claims), the ANDA number and the proposed product (strength/dosage form), the court’s key rulings (motions to dismiss, Markman/claim construction outcomes, summary judgment decisions), and the current procedural posture (trial scheduled, stayed pending USPTO reexamination, settlement entered, or final judgment).

Which patents are asserted in 1:22-cv-00181, and what claims are at issue?

A litigation-grade analysis requires:

• The specific asserted patent(s) and the asserted claims.
• How Allergan pleads each element of infringement (literal, doctrine of equivalents, or both).
• Whether infringement depends on device, method-of-use, formulation characteristics, or manufacturing steps.

Without the patent list and claim mapping, the analysis cannot be completed to a standard suitable for licensing, investment, or litigation strategy.

What is the case timeline: When was it filed and what procedural steps occurred?

A Bloomberg-style timeline would normally cover:

• Complaint filing date (and the first amended complaint, if any).
• Service and answer deadlines.
• Scheduling order milestones (Rule 16 conference, Markman date).
• Motions (dismissal, transfer, stay, preliminary injunction, summary judgment).
• PTO-related events (inter partes review, post-grant review, reexamination).
• Pretrial and trial dates.
• Settlement date or final judgment date, if applicable.

The provided input does not include docket dates or rulings, so a correct timeline cannot be produced.

Where is the litigation pending and what court orders matter for exclusivity and launch risk?

For Hatch-Waxman disputes, decision-grade impact depends on:

• Whether the court issued an infringement ruling, entered an injunction, or stayed proceedings pending USPTO review.
• Whether the case involves a “blocking” patent that is not cleared.
• Whether the court has ruled on validity or enforceability (and on which grounds).

No docket order text or summary is included in the prompt.

How strong is Allergan’s asserted patent estate in 1:22-cv-00181?

Patent strength analysis for litigation purposes typically covers:

• Remaining patent term for each asserted patent.
• Whether patents are formulation, method-of-use, or composition-of-matter.
• Prior art landscape and whether the patents have survived validity attacks in related cases.
• Claim scope breadth and typical construction outcomes in similar litigation.

No asserted-patent data is present, so strength cannot be assessed.

What claims are at risk for MSN Laboratories: invalidity, non-infringement, and carve-outs?

Generic defendants commonly pursue:

• Non-infringement by design-around (different formulation, different metes-and-bounds, different dosage regimen).
• Invalidity under § 102/103 (anticipation/obviousness) and § 112 (indefiniteness/enablement).
• Enforceability challenges (inequitable conduct), if pled.
• Patent-specific defenses linked to prosecution history and claim construction.

A claim-by-claim defense posture cannot be derived without the complaint and responsive pleadings.

Does the litigation include a Paragraph IV certification challenge and what does it imply for FDA entry timing?

In Hatch-Waxman:

• A Paragraph IV certification typically triggers this kind of suit.
• A court decision affects generic entry timing, often via an automatic 30-month stay (or its expiration/termination).

To analyze FDA entry risk, the ANDA’s certification details and the court’s current posture are required. The prompt does not provide them.

Was there a settlement or stipulated dismissal in 1:22-cv-00181, and how does that affect generic launch?

Settlement or dismissal can shift the analysis from “merits risk” to:

• Launch date agreed in a settlement.
• Carve-outs for specific strengths, dosages, or manufacturing processes.
• Patent list limitations (only certain patents remain at issue).
• Payment terms (reverse payments) if disclosed in filings.

No settlement or dismissal information is included.

Key parties and what each side typically seeks

Allergan USA, Inc.

Normally seeks:

• Judgment of infringement as to the asserted patents.
• Injunctive relief or at least a prohibition on FDA approval for the covered product.
• Costs and fees as permitted by statute and rule.

MSN Laboratories Private Limited

Normally seeks:

• Dismissal for failure to state a claim, lack of jurisdiction, or other pleading defects.
• Summary judgment of non-infringement and/or invalidity.
• A declaration of non-infringement/non-infringement and that the FDA approval can proceed (subject to timing controls).

The specific pleaded relief in 1:22-cv-00181 is not present.

Impact analysis: What does this case mean for market exclusivity, licensing, and co-marketing?

Decision-grade impact requires the identity of:

• The brand drug and strength(s) at issue.
• Whether the asserted patents are the “last-to-expire” blocking patents or peripheral patents.
• Whether there are co-owned or co-licensed patents that survive even if one patent is cleared.

No drug or Orange Book context is included in the prompt.

Key Takeaways

• The case name and docket number identify a Hatch-Waxman patent infringement dispute (Allergan v. MSN).
• A complete litigation summary and analysis cannot be produced from the provided input because the asserted patents, ANDA details, docket timeline, and rulings are not included.
• A decision-grade assessment of launch risk, settlement impact, and patent strength requires docket and pleading specifics that are not contained in the prompt.

FAQs

1. What court has jurisdiction over Allergan USA v. MSN Laboratories Private Limited (1:22-cv-00181)?
2. What is the typical purpose of filing a Hatch-Waxman infringement suit after an ANDA Paragraph IV certification?
3. How do claim construction (Markman) outcomes usually affect generic non-infringement arguments in Orange Book patent cases?
4. What procedural events most commonly determine whether generic launch proceeds before the merits are resolved?
5. How does a settlement or stipulated dismissal in a Hatch-Waxman case change FDA approval and launch timing?

References

No sources were provided in the prompt.